Sapient Capital LLC Has $12.33 Million Stock Holdings in Intuitive Surgical, Inc. $ISRG

Sapient Capital LLC trimmed its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 42.3% during the first quarter, Holdings Channel reports. The firm owned 26,752 shares of the medical equipment provider’s stock after selling 19,619 shares during the quarter. Sapient Capital LLC’s holdings in Intuitive Surgical were worth $12,331,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Pacer Advisors Inc. boosted its stake in shares of Intuitive Surgical by 38.3% during the 1st quarter. Pacer Advisors Inc. now owns 74,268 shares of the medical equipment provider’s stock worth $34,237,000 after acquiring an additional 20,550 shares during the period. Defilade Capital Management L.P. raised its stake in Intuitive Surgical by 48.2% in the 1st quarter. Defilade Capital Management L.P. now owns 67,681 shares of the medical equipment provider’s stock valued at $31,200,000 after acquiring an additional 22,019 shares during the period. FAS Wealth Partners Inc. lifted its holdings in Intuitive Surgical by 1.0% during the 1st quarter. FAS Wealth Partners Inc. now owns 5,282 shares of the medical equipment provider’s stock valued at $2,435,000 after purchasing an additional 52 shares during the last quarter. Pine Valley Investments Ltd Liability Co boosted its position in Intuitive Surgical by 30.0% during the first quarter. Pine Valley Investments Ltd Liability Co now owns 2,350 shares of the medical equipment provider’s stock worth $1,083,000 after purchasing an additional 543 shares during the period. Finally, Evansbrook LLC boosted its position in Intuitive Surgical by 5.4% during the first quarter. Evansbrook LLC now owns 1,651 shares of the medical equipment provider’s stock worth $761,000 after purchasing an additional 85 shares during the period. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Intuitive Surgical Price Performance

Shares of Intuitive Surgical stock opened at $353.33 on Monday. The company has a market capitalization of $124.82 billion, a price-to-earnings ratio of 40.47, a PEG ratio of 2.55 and a beta of 1.46. Intuitive Surgical, Inc. has a 12-month low of $328.57 and a 12-month high of $603.88. The firm’s 50-day moving average price is $398.27 and its two-hundred day moving average price is $451.13.

Intuitive Surgical (NASDAQ:ISRG) last issued its earnings results on Thursday, July 16th. The medical equipment provider reported $2.80 EPS for the quarter, beating the consensus estimate of $2.48 by $0.32. The company had revenue of $2.89 billion during the quarter, compared to analysts’ expectations of $2.83 billion. Intuitive Surgical had a net margin of 28.45% and a return on equity of 16.91%. The business’s revenue for the quarter was up 18.4% compared to the same quarter last year. During the same period in the previous year, the company earned $1.81 EPS. On average, sell-side analysts expect that Intuitive Surgical, Inc. will post 8.87 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on ISRG shares. The Goldman Sachs Group set a $558.00 price objective on shares of Intuitive Surgical in a research report on Wednesday, May 27th. Stifel Nicolaus cut their price objective on shares of Intuitive Surgical from $670.00 to $550.00 and set a “buy” rating for the company in a research report on Friday, July 17th. UBS Group started coverage on Intuitive Surgical in a report on Tuesday, July 28th. They set a “neutral” rating and a $500.00 price objective for the company. Wall Street Zen raised Intuitive Surgical from a “hold” rating to a “buy” rating in a report on Saturday, June 13th. Finally, Leerink Partners decreased their price objective on Intuitive Surgical from $573.00 to $454.00 and set an “outperform” rating on the stock in a report on Friday, July 17th. Twenty analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Intuitive Surgical presently has a consensus rating of “Moderate Buy” and a consensus target price of $509.02.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, SVP Iman Jeddi sold 5,625 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $420.55, for a total value of $2,365,593.75. Following the sale, the senior vice president owned 6,463 shares of the company’s stock, valued at approximately $2,718,014.65. This trade represents a 46.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Gary Loeb sold 400 shares of the business’s stock in a transaction on Wednesday, June 10th. The stock was sold at an average price of $424.14, for a total value of $169,656.00. Following the transaction, the executive vice president directly owned 5,720 shares of the company’s stock, valued at $2,426,080.80. This trade represents a 6.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 6,634 shares of company stock valued at $2,796,795 over the last 90 days. Corporate insiders own 0.60% of the company’s stock.

Intuitive Surgical News Summary

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: UBS upgraded ISRG, arguing that the recent selloff was excessive. The firm’s revised price target of $475 implies meaningful upside and may be supporting renewed investor interest. UBS upgrades Intuitive Surgical
• Positive Sentiment: Intuitive Surgical’s expansion beyond urology into general surgery and other specialties could create additional procedure growth and increase long-term demand for da Vinci systems, instruments and related services. Robotic surgery expansion beyond urology
• Positive Sentiment: Analyst sentiment remains broadly favorable, with the brokerage consensus at “Moderate Buy.” The company’s recurring revenue from instruments and accessories, expanding installed base and durable robotic-surgery demand remain key bullish arguments. Brokerage consensus on Intuitive Surgical
• Neutral Sentiment: Zacks highlighted the unusually high level of investor interest in ISRG, but the article did not provide a new earnings or guidance catalyst. Zacks investor attention report
• Neutral Sentiment: An executive’s small stock sales were made under a pre-arranged Rule 10b5-1 plan and reduced his holdings by roughly 2%, making them unlikely to materially alter the investment case. Intuitive Surgical insider sale
• Negative Sentiment: HSBC lowered Intuitive Surgical from Buy to Hold and set a $391 price target. Although that target remains above recent trading levels, the downgrade signals reduced confidence in the stock’s near-term upside. HSBC downgrades Intuitive Surgical
• Negative Sentiment: Despite a quarterly revenue and earnings beat, investors remain concerned about softer U.S. procedure growth, deferred care and the premium valuation. Those worries have contributed to continued pressure in the shares. Intuitive Surgical post-earnings selloff

Intuitive Surgical Company Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.